❌

Reading view

STAT+: A drug that was ‘engineered with AI’ enters Phase 3 testing

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. My colleagues will be in Orlando later this week for the American Society of Hematology meeting. Sign up for their newsletter to stay on top of the news from the conference. We’re also holding an event there on Friday.

Fight around hospital drug discount program escalates with new lawsuit

The American Hospital Association and several hospital systems have filed a lawsuit against the Trump administration, seeking to halt an upcoming pilot program for a controversial drug discount program.

Continue to STAT+ to read the full story…

© Adobe

  •  

STAT+: Chinese government’s support for biotech fuels huge rally

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, we just had our first snow of the season in Chicago, I just ordered a pie for Thanksgiving, and I’m still in denial that the year is almost ending.

Onto the news today.

Continue to STAT+ to read the full story…

© PHILIPPE LOPEZ/AFP/Getty Images

  •  

STAT+: Natera, known for spotting cancer recurrence, wades into early detection

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. It seems everyone I know has been getting sick lately — hope you are all taking care of yourselves! Onto the news today.

BridgeBio notches another Phase 3 win

BridgeBio said this morning that its investigational drug succeeded in a late-stage trial of patients with autosomal dominant hypocalcemia type 1, a rare genetic condition that causes low calcium levels in the blood.

Continue to STAT+ to read the full story…

© Adobe

  •  
❌